Details of the Drug

General Information of Drug (ID: DMK7OHI)

Drug Name
INCAGN01949
Indication
Disease Entry ICD 11 Status REF
Advanced malignancy 2A00-2F9Z Phase 2 [1]
Metastatic malignant neoplasm 2D50-2E09 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DVCN93
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
OX40L receptor (CD134) TTL31H0 TNR4_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Advanced malignancy
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
OX40L receptor (CD134) DTT TNFRSF4 2.17E-06 1.01 1.66
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02923349) A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
2 Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655.